Xap Therapeutics, formerly known as Rockend Ltd., is a start-up biotechnology company which is developing an innovative, synthetic biology driven platform for cell therapeutics. Based in Cambridge, UK, the company was founded by a group of experienced biotech entrepreneurs with significant funding from well-known US/UK blue-chip VCs. Xap Therapeutics applies CRISPR technology to engineer iPSCs. These iPSCs form the basis of a universal cell platform producing a “chassis” cell, which we can further functionalise into cell therapies by expression of genetically engineered constructs. Our cell products will have the ability to process external cues via engineered receptors and to release various types of cargos upon activation. The ultimate aim is to create novel cell therapies with mechanisms of action that are beyond reach of current approaches, thus bringing a step change improvement in the treatment of serious disease, including autoimmunity and cancer.